AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1778 participants.
Also called NCT07797335
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,778 participants
- Sponsor
- Registry
-
NCT07797335
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Bulgaria, Canada, China, Czechia, Germany, Greece, India, Italy, Mexico, Poland, Spain, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07797335. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2028-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Acronym
- AMBITION 7
- Condition
- Type 2 Diabetes
- Condition
- Cardiovascular Risk
- Intervention (Drug)
- Zenagamtide
- Intervention (Drug)
- Insulin glargine U-100
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07797335- Content hash
744aca3e10969e1315a9afbc684fcb62203cc605bb0dab825a96d268ca8c27b5